Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia

被引：0
|
作者：
Dawn E. Colburn
Deborah A. Thomas
Francis J. Giles
机构：
[1] The University of Texas,Department of Leukemia
[2] M.D. Anderson Cancer Center,undefined
来源：
Investigational New Drugs | 2003年 / 21卷
关键词：
paclitaxel; refractory; acute lymphocytic leukemia; adult;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3–4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.
引用
收藏
页码：109 / 111
页数：2
相关论文
共 50 条
  • [1] Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia
    Colburn, DE
    Thomas, DA
    Giles, FJ
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (01) : 109 - 111
  • [2] Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia
    Abbi, Kamal K. S.
    Rybka, Witold
    Ehmann, W. Christopher
    Claxton, David F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01) : 41 - 46
  • [3] Relapsed acute lymphocytic leukemia
    Robert J. Wells
    Current Oncology Reports, 2008, 10 : 451 - 452
  • [4] Relapsed Acute Lymphocytic Leukemia
    Wells, Robert J.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 451 - 452
  • [5] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [6] Agents for refractory/relapsed acute lymphocytic leukemia in adults
    Qian, L. -R.
    Fu, W.
    Shen, J. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (17) : 2465 - 2474
  • [7] Treatment of adult patients with acute lymphocytic leukemia in relapse
    Mazza, JJ
    Leong, T
    Rowe, JM
    Wiernik, PH
    Cassileth, PA
    LEUKEMIA & LYMPHOMA, 1996, 20 (3-4) : 317 - 319
  • [8] Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
    Bokemeyer, C
    Beyer, J
    Metzner, B
    Ruther, U
    Harstrick, A
    Weissbach, L
    Kohrmann, U
    Verbeek, W
    Schmoll, HJ
    ANNALS OF ONCOLOGY, 1996, 7 (01) : 31 - 34
  • [9] A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Lioure, Bruno
    Kim, Stella K.
    Atallah, Ehab
    Leguay, Thibaut
    Kelly, Kevin
    Marolleau, Jean-Pierre
    Escoffre-Barbe, Martine
    Thomas, Xavier G.
    Cortes, Jorge
    Jabbour, Elias
    O'Brien, Susan
    Bories, Pierre
    Oprea, Corina
    Hatteville, Laurence
    Dombret, Herve
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (03) : 139 - 145
  • [10] A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia
    Tavernier-Tardy, E.
    Cornillon, J.
    Molucon-Chabrot, C.
    Cahn, J. Y.
    Tinquaut, F.
    Bourmaud, A.
    Guyotat, D.
    Thomas, X.
    HEMATOLOGY, 2017, 22 (04) : 217 - 223
12345